RxDoctor Payments DataLook up a doctor →

Mohammed Masri, MD

Hematology & Oncology · Mount Clemens, MINPI 1669409439

Payments from drug & device makers

$252,589in general payments, 2019–2025

Across 584 payments — averaging $432.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$93K
  • Valencia Technologies Corporation$50K
  • Eli Lilly$42K
  • Merck$23K
  • Bristol Myers Squibb$21K
  • Helsinn Healthcare SA$11K
  • plus $13K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
E.r. Squibb & Sons, L.L.C.25$93,077
Valencia Technologies Corporation4$50,000
Eli Lilly4$41,715
Merck58$23,069
Bristol Myers Squibb19$20,958
Helsinn Healthcare SA1$10,625
Pharmacyclics LLC, An Abbvie Company14$2,132
GSK5$2,028
Genentech USA, Inc.53$904
Novartis56$870
Johnson & Johnson(2 entities)45$618
Astellas Pharma US Inc17$598
Lilly USA, LLC17$491
Sanofi24$473
Eisai Inc.30$461
AbbVie16$452
AstraZeneca20$360
Incyte Corporation12$298
Daiichi Sankyo Inc.14$291
Seagen Inc.10$252
Pfizer13$218
Amgen10$186
Ipsen Biopharmaceuticals, Inc8$160
Takeda Pharmaceuticals U.S.A., Inc.6$143
Kerecis Limited1$140
AVEO Pharmaceuticals, Inc.3$140
Sobi, Inc7$136
Gilead(2 entities)7$128
Blueprint Medicines Corporation5$113
Taiho Oncology, Inc.6$111
Bayer5$108
Sanofi-aventis U.S. LLC1$100
Caris MPI, Inc.3$83
Agios Pharmaceuticals, Inc.5$82
Array Biopharma Inc4$71
Pharmaessentia USA Corporation3$67
Servier Pharmaceuticals LLC4$63
Beone Medicines USA, Inc.3$63
Deciphera Pharmaceuticals Inc.3$54
Beigene USA, Inc.3$54
G1 Therapeutics, Inc.3$51
Puma Biotechnology, Inc.3$51
Dova Pharmaceuticals3$44
Genmab U.S., Inc.2$43
Regeneron Healthcare Solutions, Inc.2$43
Myriad Genetic Laboratories, Inc.2$41
Stemline Therapeutics Inc.2$40
Clovis Oncology, Inc.3$38
Pharmacosmos Therapeutics Inc.2$34
Adaptive Biotechnologies Corporation2$32
Dendreon Pharmaceuticals LLC1$23
Exelixis Inc.1$22
Tersera Therapeutics LLC1$22
Syndax Pharmaceuticals, Inc.1$20
Mylan Institutional Inc.1$20
Kyowa Kirin, Inc.1$19
Pharmaand GmbH1$19
Tolmar, Inc.1$19
Azurity Pharmaceuticals, Inc.1$18
Karyopharm Therapeutics Inc.1$17

How this compares

$252,589 in reported general payments places this provider in the 85th percentile of 282 hematology & oncology providers in Michigan.

See all hematology & oncology providers in Michigan →

Medicare billing

Part B allowed, 2024
$93,365
Medicare patients
252
Services billed
837

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Mount Clemens

See the full list for Michigan →

Where these figures come from

Is this you, or does something look wrong? →